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Summary
Objective:  The  authors  present  the  guidelines  of  the  French  Society  of  Oto-Rhino-Laryngology
and Head  and  Neck  Surgery  (SFORL)  on  patient  information  ahead  of  thyroid  surgery.
Methods:  A  multidisciplinary  medical  team  was  tasked  with  a  scientiﬁc  literature  review  on
this topic.  The  texts  retrieved  were  analyzed  by  an  independent  committee.  A  joint  meeting
drew up  the  ﬁnal  guidelines.  The  strength  of  the  recommendations  (grade  A,  B  or  C)  was  based
on levels  of  evidence.
Results:  It  is  recommended  that  the  results  of  preoperative  exploration  and  the  indications
for surgery  should  be  explained  to  the  patient.  Patients  should  be  informed  as  to  the  type  of
,  rissurgery, surgical  objectives
written  consent  before  surgery.
Conclusion:  Appropriate  medica
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http://dx.doi.org/10.1016/j.anorl.2013.04.001ks  and  consequences.  It  is  mandatory  to  obtain  the  patient’sl  information  is  a  critical  step  in  patient  management.
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Table  1  Levels  of  evidence  and  guideline  grades.
Level  of  evidence  from  the  literature  Guideline
grade
Level  1  Grade  A
High-power  randomized  comparative
studies
Established
proof
Meta-analysis  of  randomized
comparative  studies
Decision  analysis  based  on
well-conducted  studies
Level  2 Grade  B
Low-power  randomized  comparative
studies
Scientiﬁc
presumption
Well-conducted  non-randomized
comparative  studies
Cohort  studies
Level  3  Grade  C
Case-control  studies  Low  level  of
evidence
Comparative  studies  with  historical
series
Level  4
Comparative  studies  with  serious  bias
Retrospective  studies
Case  series
Descriptive  epidemiological  studies
(transverse,  longitudinal)
Any  other  publication  (case  report,
expert  opinion,  etc.)
Professional
agreement
No  publication
Table adapted from Sackett Score, following the ANAES guide to
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atient  information  is  an  essential  step  in  management
ith  major  impact  on  treatment  satisfaction.  It  underpins
he  quality  of  the  physician—patient  relationship  and  the
atient’s  compliance.
The  present  good-practice  guidelines  are  intended  to
rovide  fellow-surgeons  who  perform  thyroidectomy  with
alidated  data  for  adherence  to  rules  of  good  clinical
ractice  and  for  answering  their  patients’  questions.  The
uidelines  are  based  on  the  scientiﬁc  literature  and  on
urrent  regulations.  The  aim  is  to  guide  decision  making,
armonize  practice  and  reduce  unnecessary  surgery,  and
lso  to  help  establish  a  relation  of  conﬁdence  between  sur-
eon  and  patient.
The  text  comprises  three  sections,  dealing  respectively
ith  patients’  right  to  information,  the  content  of  that
nformation,  and  the  modalities  of  its  communication.  The
ontents  section  is  presented  in  the  form  of  answers  to
atients’  questions,  following  the  pattern  of  a typical
onsultation.
For  editorial  reasons,  the  present  article  includes  only
hort  versions  of  the  rationales  and  reference  list;  the
ull  French  text  with  complete  rationale  and  exhaus-
ive  reference  list  is  available  at  the  SFORL  website:
ttp://www.sforl.org/.
ethod
 multidisciplinary  work  group  was  set  up  and  tasked  to  carry
ut  a  review  of  the  scientiﬁc  literature  on  the  topic.  The
roup  met  several  times  and  drew  up  the  analysis  the  guide-
ines  were  to  be  based  on.  The  resulting  texts  were  read  over
y  an  independent  committee.  A  full  team  meeting  drew  up
he  ﬁnal  guidelines.
The  guidelines  were  graded  A,  B  or  C  according  to
ecreasing  level  of  evidence,  in  line  with  the  ANAES  French
ealth  authority  guide  to  literature  analysis  and  grading  of
uidelines  of  January  2000  (Table  1).  This  classiﬁcation  is
ntended  to  clarify  the  basis  of  the  guidelines.
uidelines
atients’  rights  to  and  wish  for  information
atients’  right  to  information  in  France  follows  from  two
ain  legal  texts:
 the  law  of  4  March  2002  concerning  patients’  rights  and
health  system  quality;
 the  European  Charter  of  Patients’  Rights.
Three  rights  are  to  be  distinguished:
 a  right  to  information:  each  person  has  the  right  to  access
all  information  regarding  their  state  of  health; a  right  to  informed  consent:  each  person  has  the  right
to  access  all  information  enabling  them  to  be  actively
involved  in  decisions  concerning  their  health;  such  infor-
mation  is  a  preliminary  to  any  procedure  or  treatment;
s
d
t
mliterature analysis and grading of guidelines of January.
 a right  to  freedom  of  choice:  each  person  has  the  right  to
freely  choose  between  the  various  treatment  procedures
on  the  basis  of  appropriate  information.
The  physician  should  thus  inform  the  patient  of  the
arious  possible  treatments,  their  usefulness,  the  possible
rgency  of  implementing  them,  the  foreseeable  frequent
r  serious  risks  involved  and  the  foreseeable  consequences
f  refusing  treatment.  This  obligation  is  fully  applicable  in
he  case  of  thyroid  pathology,  where  clinically  serious  and
rgent  situations  are  rare  and  where  alternative  treatments
r  means  of  management  are  often  available  [1,2]  (level  of
vidence  1).  Without  going  into  the  ethical  debate  about
he  ﬁnality  of  information,  there  is  a link  between  infor-
ation  and  satisfaction  in  surgery  patients.  Information  on
he  patient’s  health  is  compiled  in  the  medical  records  and
hould  enable  better  communication  between  the  various
hysicians  involved  in  the  patient’s  management  and  with
he  actual  patient.  Applying  these  principles  in  the  surgical
etting  thus  obliges  the  surgeon  to  prioritize  the  medical
ata  according  to  two  criteria:  the  information  transmit-
ed  should  be  validated  and  should  be  relevant  to  decision
aking.
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dPatient  information  ahead  of  thyroid  surgery  
Guideline  1
The  patient  should  be  informed  as  to  the  organization  of
his  or  her  care,  and  this  information  should  be  updated  at
each  step  of  management.  The  information  provided  should
be  complete,  honest  and  individualized.  The  practitioner
should  facilitate  access  to  this  information  and  help  the
patient  understand  the  medical  facts  underlying  the  recom-
mendation  of  surgery  (GRADE  A).
Information  contents
A  mandatory  body  of  information  is  intended  to  allow  the
patient  to  give  informed  consent,  and  to  answer  surgery
candidates’  usual  questions;  this  is  to  be  supplemented
according  to  the  patient’s  individual  characteristics  and
requirements.
‘‘What  clinical  and  paraclinical  data  are  required  before
indicating  thyroidectomy?’’
The  surgeon  plays  a  central  role  in  patient  information,
despite  usually  having  been  brought  in  by  the  family  physi-
cian  or  an  endocrinologist.  Initial  clinical  examination  is
completed  by  complementary  examinations  to  identify  thy-
roid  pathology  or  suspicion  of  cancer.
The  interview  screens  for  personal  history  of  cervical  irra-
diation  and  familial  history  of  thyroid  cancer.  Functional
signs,  notably  of  compression,  are  noted.  Clinical  exami-
nation  details  thyroid  gland  characteristics  and  any  cervical
adenopathies,  and  assesses  the  voice  and,  if  necessary,  vocal
fold  mobility  [1,2]  (level  of  evidence  1).
Endocrine  biological  analysis  includes  systematic  TSH
assay;  calcitonin  assay  is  a  matter  of  debate,  although
included  in  current  French  recommendations  [1,2]  (level  of
evidence  4).
Ultrasound  is  the  key  initial  examination.  It  determines
the  characteristics  of  palpable  lesions,  and  may  also  reveal
other  non-palpable  intrathyroid  or  lymph-node  lesions  [1—3]
(level  of  evidence  1).
Fine-needle  aspiration  is  best  performed  under  ultra-
sound  guidance,  and  diagnoses  the  type  of  the  nodular
lesions  selected  on  ultrasound  [1—3]  (level  of  evidence  1).
Results  should  be  reported  on  the  Bethesda  2010  classiﬁca-
tion,  to  improve  communication  between  physicians  [4—6]
(level  of  evidence  4).  The  patient  should  be  informed  of
the  management  guidelines  validated  by  scientiﬁc  societies
regarding  ﬁne-needle  aspiration  cytology  ﬁndings.
Scintigraphy  is  indicated  only  in  case  of  low  TSH  level,
to  differentiate  between  Graves-Basedow  disease,  a  single
toxic  nodule  and  a  toxic  or  pretoxic  multinodular  goiter  [2,7]
(level  of  evidence  1).  CT  and  MRI  are  reserved  for  certain
anatomo-clinical  forms  (plunging  goiter,  locally  advanced
cancer,  etc.)  [2]  (level  of  evidence  4).  PET-CT  is  not  recom-
mended  for  indicating  surgery  in  nodular  pathology  [2]  (level
of  evidence  2),  although  nodules  discovered  serendipitously
on  PET-CT  (incidentalomas)  are  associated  with  a  signiﬁcant
risk  of  cancer  [8]  (level  of  evidence  4).Guideline  2
Results  of  the  preoperative  examinations  indicating  surgery,
and  notably  of  ultrasound,  cytology  (and  scintigraphy,  if
i
c
d
a365
erformed)  and  endocrine  biology  should  be  explained  to
he  patient  (GRADE  A).
‘Why  do  I  need  to  have  a  thyroid  operation?’’
his  question  should  be  answered  on  the  basis  of  the
uidelines  laid  down  by  scientiﬁc  societies  for  the  imple-
entation  of  personalized  evidence-based  medicine  taking
he  patient’s  expectations  and  wishes  into  account  as  well
s  the  personal  experience  of  the  physician  and  team  [1,2]
level  of  evidence  1).
Surgery  is  recommended  in  case  of  malignant  or  suspect-
dly  malignant  nodule  according  to  clinical,  ultrasound  and
iological  ﬁndings  (clear  elevation  in  serum  calcitonin)  or
ytology  results  (malignancy-positive  or  suspect  ﬁne-needle
spiration  cytology,  vesicular  or  oncocytic  neoplasm)  [1,2]
level  of  evidence  1).  Surgery  is  likewise  recommended  in
ase  of  signs  of  compression  or  of  hyperthyroid  multinodular
oiter  [1]  (level  of  evidence  1).  In  Graves-Basedow  disease,
ollowing  failure  of  or  contraindications  for  medical  treat-
ent  and  in  case  of  hyperfunctional  nodule,  surgery  and
adiation  therapy  may  be  considered  [7]  (level  of  evidence
).
uideline  3
he  patient  should  be  informed  that  surgery  is  indicated
hen  cancer  is  diagnosed  or  suspected  and  in  case  of
ymptomatic  benign  nodular  lesions  or  hyperthyroid  multin-
dular  goiter.  Patients  should  be  informed  that  they  and
heir  physicians  are  to  discuss  the  proposed  operation
n  case  of  Graves-Basedow  disease,  hypersecreting  nod-
le  or  large  asymptomatic  or  plunging  nodule  (GRADE
).
‘Do  I  have  to  have  all  my  thyroid  gland  removed?’’
he  surgeon  should,  in  all  cases,  discuss  with  the  patient  the
ype  of  thyroidectomy  to  be  performed  (lobectomy,  total
hyroidectomy,  isthmectomy)  and  the  reasons  for  advis-
ng  one  procedure  rather  than  another.  In  case  of  pre-
r  per-operative  diagnosis  of  cancer,  total  thyroidectomy
s  recommended  [1,2]  (level  of  evidence  1).  The  patient
hould  be  informed  of  the  possibility  of  two-step  surgery
n  case  of  pre-  or  per-operative  difﬁculty  in  diagnosis.  Pres-
nce  of  bilateral  nodules  of  indeterminate  type,  signs  of
ompression  or  of  Graves-Basedow  disease  are  likewise  indi-
ations  for  total  thyroidectomy  [1,2,7]  (level  of  evidence  1).
omplementary  information  regarding  possible  lymph-node
urgery  and  its  beneﬁts  and  risks  is  to  be  given  for  cancer
atients  [1,2]  (level  of  evidence  2).
uideline  4
he  patient  should  be  informed  that,  when  surgery  has
een  decided  on,  total  thyroidectomy  is  indicated  for
ancer,  diffuse  multinodular  goiter  and  Graves-Basedow
isease.  For  benign  isolated  unilateral  nodular  lesions,  lobo-
sthmectomy  or  isthmectomy  are  indicated.  For  goiter,  the
hoice  between  total  thyroidectomy  and  lobo-isthmectomy
epends  on  the  number,  size,  ultrasound  characteristics,
natomic  situation  and  evolutivity  of  the  nodules.
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In  all  cases,  the  arguments  as  to  the  choice  and  type
f  surgery  proposed  with  its  risks  and  beneﬁts  should
e  explained  to  and  discussed  with  the  patient  (GRADE
).
‘What  are  the  risks  and  complications  of  thyroid
urgery?’’
nformation  regarding  the  ‘‘foreseeable  frequent  or  seri-
us’’  risks  of  thyroidectomy  is  based  on  validated  literature
ata,  the  patient’s  personal  situation  and  the  surgeon’s
xperience.
A  distinction  is  to  be  made  between  on  the  one  hand
isks  common  to  all  thyroid  surgery,  regarding  which  the
atient  should  be  informed  as  to  their  clinical  expression
nd,  succinctly,  their  mechanisms  and  average  incidence  in
ublished  series,  and  on  the  other  hand  risks  speciﬁc  to  the
atient’s  pathology  and  individual  characteristics  (age  and
omorbidity).
Postoperative  hematoma  is  a  rare  but  potentially  severe
omplication  due  to  the  risk  of  compression  [9,10]  (level
f  evidence  4),  [11]  (level  of  evidence  2),  [12—14]  (level
f  evidence  4).  Unilateral  laryngeal  palsy  due  to  recur-
ent  nerve  lesion  (recurrent  nerve  palsy)  occurs  in  2%  to
%  of  cases,  in  half  of  which  it  is  deﬁnitive  [9,12,14]  (level
f  evidence  1).  It  induces  dysphonia  of  variable  severity,
haracterized  by  a  weak  breathy  voice.  Bilateral  involve-
ent  is  exceptional  but  may  lead  to  severe  inspiratory
yspnea.  Vocal  impairment,  especially  of  the  singing  voice,
ay  be  induced  by  uni-  or  bi-lateral  lesion  to  the  exter-
al  branch  of  the  superior  laryngeal  nerve  [13,14]  (level
f  evidence  4).  There  is  a  signiﬁcant  risk  (20—30%)  of
ransient  hyperparathyroidism,  but  a  much  lower  risk  of
eﬁnitive  hyperparathyroidism,  at  around  1—6%,  increasing
ith  and  proportionally  to  central  compartment  lymph-node
esection;  the  risk  is  likewise  elevated  in  Graves-Basedow
isease  [12,13]  (level  of  evidence  4),  [15]  (level  of  evidence
).
The  other  risks  associated  with  thyroid  surgery  are  rare:
urgery-site  infection,  tracheal  necrosis,  minor  swallow-
ng  disorder,  hypertrophic  or  cheloid  scarring,  and  general
on-speciﬁc  complications  (e.g.,  deep  venous  thrombosis
nd  pulmonary  embolism)  [9,10,12—14]  (level  of  evidence
).
Overall,  thyroid  surgery  is  considered  and  may  be  pre-
ented  to  the  patient  as  associated  with  a  low  rate  of
eﬁnitive  complications,  although  an  over-optimistic  pre-
entation  of  risk  may  be  considered  as  a  failure  to  inform
opinion  of  work-group  experts).
uideline  5
he  patient  should  be  informed  of  the  frequent,  serious  and
xceptional  risks  inherent  to  the  proposed  procedure,  and
f  laryngeal  (respiratory,  phonatory  and  swallowing-related)
nd  parathyroid  risks  in  particular.Information  should  not  be  limited  to  strictly  surgical  risk.
The  risk  presentation  should  be  tailored  to  the  patient’s
ndividual  situation,  taking  account  of  the  particular  pathol-
gy  and  the  type  of  procedure  (GRADE  A).
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‘If  I agree  to  surgery,  what  useful  information  should  I
eceive?’’
hyroid  gland  surgery  is  scheduled  surgery  which  is  only
xceptionally  urgent,  thus  allowing  speciﬁc  information  as
o  the  means  of  surgical  management.
oncerning  the  health  establishment
he  decree  dated  December  28,  2010  lays  down  the  con-
itions  under  which  health  establishments  make  published
esults  on  care  quality  and  safety  indicators  available  to  the
ublic  each  year:  nosocomial  infection,  surgical  site  surveil-
ance,  etc.  Thyroid  cancer  surgery  should  be  performed
n  approved  cancer  centers,  which  implement  transverse
uality  measures  in  line  with  the  French  National  Cancer
nstitute’s  guidelines.
oncerning  the  surgeon  and  surgery  team
ertain  thyroid  procedures  (in  Graves-Basedow  disease,
ocally  advanced  cancer,  recurrence,  children,  etc.)  are  best
erformed  by  teams  with  strong  speciﬁc  experience  [16]
level  of  evidence  4).
oncerning  anesthesia  risks,  type  of  anesthesia  and  type
f  admission
hyroid  surgery  is  usually  performed  under  general  anes-
hesia  with  orotracheal  intubation.  In  selected  cases  it  may,
owever,  be  performed  under  local  or  locoregional  anesthe-
ia,  possibly  associated  to  sedation  [13]  (level  of  evidence
),  [17]  (level  of  evidence  2);  in  such  cases,  it  is  the
esponsibility  of  the  anesthesiologist  to  provide  appropri-
te  information,  in  liaison  with  the  surgeon.  The  type  of
dmission  (outpatient  or  inpatient)  is  to  be  discussed  with
he  anesthesiologist  and  explained  to  the  patient.
oncerning  extemporaneous  anatomocytopathology
xamination
xtemporaneous  anatomocytopathology  examination  is  nei-
her  systematic  nor  mandatory;  the  patient  should  be
nformed  if  it  is  to  be  performed  and  about  its  limitations
nd  potential  consequences  [18]  (level  of  evidence  2),  [19]
level  of  evidence  4).
oncerning  technical  means
echnical  means  are  partly  team-speciﬁc.  The  surgeon
hould  inform  the  patient  as  to  his  or  her  own  speciﬁc  means,
he  probable  duration  of  surgery  and  the  use  of  any  tech-
iques  that  are  still  under  evaluation.
In  reputedly  difﬁcult  procedures  such  as  for  recurrence
nside  the  thyroidectomy  space,  locally  advanced  cancer  or
arge  hyperthyroid  goiter,  laryngeal  neuromonitoring  may  be
 helpful  technical  aid  for  the  surgeon,  but  does  not  reduce
he  risk  of  inferior  laryngeal  nerve  lesion  [20]  (level  of  evi-
ence  1),  [21]  (level  of  evidence  2).
oncerning  the  postoperative  period
ain  and  nausea  are  not  unusual  during  the  ﬁrst  postop-
rative  night.  The  duration  of  hospital  stay  depends  on
he  type  of  surgery,  multiple  pathology  and  comorbidity,
omplications  and  the  team’s  particular  habits  [22]  (level
f  evidence  4).
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GPatient  information  ahead  of  thyroid  surgery  
Concerning  follow-up  and  cicatrization
A  postoperative  consultation  with  the  surgeon  is  scheduled
systematically  to  examine  the  patient,  advise  on  scar  care,
communicate  deﬁnitive  pathology  ﬁndings  and  check  that
handover  to  the  family  physician,  endocrinologist  and/or
nuclear  physician  has  been  set  up  (opinion  of  work-group
experts).
Guideline  6
The  patient  should  be  informed  as  to  the  team  and  center’s
methods  of  medical  and  surgical  management.  In  case  of
outpatient  management,  the  patient  should  be  informed  of
the  speciﬁc  means  and  restrictions  involved  (GRADE  A).
‘‘Is  there  any  other  treatment  than  surgery  for  my
pathology?’’
After  providing  full  information  as  to  why  surgery  is  being
suggested  and  the  means  and  risks  involved,  the  patient
should  also  be  informed  of  alternative  treatments  and  the
consequences  of  not  agreeing  to  the  proposal.  Surgery  is
intended  to  manage  three  different  health  problems:  hyper-
thyroidism,  compression  syndrome  and  the  risk  of  cancer.
Alternatives  should  be  discussed  for  each.  In  cancer,  surgery
is  the  only  means  of  deﬁnitely  conﬁrming  diagnosis  and  is
also  the  reference  treatment.  Surgery  is  also  the  treatment
of  choice  for  compressive  goiter.  Radiation  therapy  is,  how-
ever,  an  effective  alternative  in  Graves-Basedow  disease  and
hyperfunctional  nodule  [1,2,7]  (level  of  evidence  1).
‘‘What  will  the  consequences  of  the  operation  be?’’
Answering  this  question  involves:  the  endocrine  conse-
quences  of  partial  or  total  resection  of  the  thyroid  gland
(weight  gain,  time  of  convalescence),  possible  general
impact  of  surgery,  means  of  surveillance  of  any  remaining
thyroid  lobe,  and  hormone  replacement  or  inhibition  ther-
apy.
Weight  gain,  even  slight,  is  most  frequent  in  menopausal
women,  especially  when  not  under  hormone  replacement
therapy,  and  when  surgery  was  for  hyperthyroidism  [23]
(level  of  evidence  4),  [24]  (level  of  evidence  2).  Except
in  special  cases,  convalescence  lasts  between  1  and  3
weeks  (opinion  of  work-group  experts).  Following  par-
tial  thyroidectomy,  replacement  therapy  is  only  mandatory
when  residual  thyroid  tissue  is  insufﬁcient  for  euthyroidism
[1]  (level  of  evidence  2).  Following  total  thyroidectomy,
deﬁnitive  hormone  replacement  therapy,  usually  by  levothy-
roxine,  should  be  initiated  [25]  (level  of  evidence  2),  and
adapted  according  to  clinical  symptomatology  and  biological
ﬁndings  (TSH  assay).
Guideline  7
The  patient  should  be  informed  of  the  endocrine  impact
of  thyroidectomy.  The  need  for  speciﬁc  medical  follow-up
and  deﬁnitive  hormone  replacement  therapy  after  total  thy-
roidectomy  should  be  stressed.  Postoperative  care  should
be  coordinated  with  the  family  physician,  endocrinologist
and/or  nuclear  physician  (GRADE  A).
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eans  of  communication:  how  to  inform  effectively
here  are  no  regulations  or  studies  clearly  deﬁning  how  to
chieve  effective  information.  This  is  a  very  difﬁcult  ques-
ion,  as  any  clear  and  precise  deﬁnition  of  what  ‘‘effective
nformation’’  means  is  open  to  interpretation,  depending
n  the  point  of  view  adopted  (the  patient’s,  the  physician’s,
he  lawyer’s,  judge’s,  teacher’s,  philosopher’s,  consumer’s,
tc.)  and  on  the  individual  patient’s  level  of  knowledge  and
f  concern  as  well  as  on  the  seriousness  of  the  pathology  in
uestion.
To  improve  understanding  and  if  the  patient  so  wishes,
nformation  may  best  be  delivered  in  the  presence  of  a  per-
on  or  persons  of  his  or  her  choosing.  The  law  of  March  4,
002  also  requires  the  surgeon  to  suggest  designating  a  per-
on  of  trust  to  be  consulted  should  the  patient  be  unable  to
ake  his  or  her  wishes  clear.
Oral  information  is  sufﬁcient  for  consent  to  be  obtained,
xcept  when  the  law  requires  a  form  to  be  signed
e.g.,  tissue  conservation  in  a  tumor-bank  and  biomedical
esearch).  The  surgeon  should  explain  the  risks  of  surgical
omplications  in  clear  and  simple  terms  (using  diagrams),
he  likelihood  of  the  patient  developing  such  complications,
heir  reversibility  or  not,  and  the  treatments  available.
A  written  information  document  is  a  back-up  to  oral  infor-
ation.  It  is  intended  to  inform  and  enrich  the  patient’s
hinking  during  the  period  of  reﬂection;  it  has  to  be  detailed
nd  comprehensible  for  a  non-specialist.  According  to  the
rench  Health  Authority  (HAS),  when  written  documents
xist,  they  should  be  given  to  the  patient  so  that  he  or
he  can  refer  to  them  and/or  discuss  them  with  any  per-
on  of  choice,  particularly  the  caregiving  physicians;  their
eal  contribution,  however,  is  limited  by:
 the  poor  quality  of  certain  information  sheets;
 poor  understanding  of  written  medical  information  for  a
non-negligible  percentage  of  patients;
 and  the  fact  that  a  large  number  of  patients  are  of  the
opinion  that  the  main  purpose  of  such  written  information
documents  is  to  safeguard  the  institution  or  doctors  in
case  of  subsequent  conﬂict  [26]  (level  of  evidence  3),  [27]
(level  of  evidence  2).
Effective  information  should  avoid  certain  mistakes:
 having  the  information  delivered  by  the  wrong  person:  a
colleague  (intern)  or  co-worker  (nurse)  or  the  institution
(administrative  staff);
 delivering  the  wrong  contents:  informing  only  about  risks
without  advice  as  to  the  optimal  treatment  approach;
 mistaken  objectives:  failing  to  ensure  real  understanding.
The  physician’s  approachability  and  explanations  that  are
ersonalized  and  adapted  to  the  patient’s  personality  and
evel  of  knowledge  are  the  keys  to  good-quality  information
opinion  of  work-group  experts).
uideline  8t  is  mandatory  to  obtain  the  patient’s  written  consent
head  of  surgery,  which  entails  providing  sufﬁcient,  adapted
nd  good-quality  information.  Surgeons  should  deliver  this
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nformation  themselves  orally,  explaining  why  surgery  is  the
reatment  best  adapted  to  the  patient’s  condition.  The  sur-
eon  should  ensure  the  patient’s  good  understanding  and
chedule  a  reasonable  period  of  reﬂection  before  surgery.  In
ase  of  difﬁculty  in  delivering  information,  a  second  opinion
ay  be  advised.  A  written  information  document  is  a  good
dea,  but  not  mandatory  unless  required  by  law  (biomedical
esearch,  genetic  analysis).  The  document,  well-kept  medi-
al  records  and  records  of  correspondence  with  the  patient’s
amily  physician  are  the  elements  a  legal  advisor  will  be
ooking  for  in  case  of  conﬂict  (GRADE  A).
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